From TokenPost · · 40s
Moderna Shares Jump 11.04% Before Melanoma Trial Data
Moderna shares rise 11.04% as melanoma trial data approaches.
In brief
Moderna shares rise 11.04% as melanoma trial data approaches. Moderna stock climbed 11.04% ahead of Phase 3 melanoma trial results presentation. Originally reported by TokenPost.
Moderna Shares Rise
Moderna shares climbed 11.04% over two sessions, closing at $242.08 on Oct. 20 as investors awaited detailed Phase 3 results for its melanoma treatment with Merck.
Trial Results Scheduled
Detailed trial results for intismeran autogene with Keytruda are set for presentation Saturday, Oct. 24, at 10:30 a.m. ET.
Stock Performance
Shares rose 4.07% on Oct. 19 and 6.69% on Oct. 20, climbing 284.5% from $62.96 on Aug. 18.
What to remember
Moderna stock climbed 11.04% ahead of Phase 3 melanoma trial results presentation.
